Background:Studies have demonstrated improved clinical outcomes with extended infusion(EI)piperacillin/tazobactam(TZP)compared to standard infusion(SI).However,there is less evidence on its benefits in noncritically-i...
Objective: to investigate the clinical value of piperacillin/tazobactam in the treatment of pediatric sepsis. Methods: 68 cases of sepsis patients admitted to our hospital from February 2019 to August 2021 were random...
Peking University Third Hospital research funding(Grant No.7476-01)
In the present study, we aimed to investigate the optimal dosage regimens of piperacillin/tazobactam in patients with chronic kidney disease according to their different classes of renal function based on bacterial re...
Antibiotics cause 36 percent of all cases of drug-induced AKI (acute kidney injury). Research suggests that drug-induced AKI increases hospital length of stay, ventilator days and mortality. The purpose of this stud...
We retrospectively evaluated the efficacy and safety of the combination drug piperacillin/tazobactam (PIPC/TAZ) in comparison with those of fourth-generation cephalosporins (4th Cephs) as initial empirical treatment i...
Objective To compare the efficacy and safety of two β lactam β lactamase inhibitor combinations, piperacillin/tazobactam and ticarcillin/clavulanic acid in the treatment of bacterial infections. Methods A ra...